Please login to the form below

Not currently logged in


This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.

China’s Innovent to start US trials of anti-CD47 cancer drug

China’s Innovent to start US trials of anti-CD47 cancer drug

Sintilimab will be initially positioned for the Chinese market. Chinese biotech Innovent Biologics has been given approval by the FDA to start trials of an antibody that targets CD47, an emerging

Latest news

More from news
Approximately 20 fully matching, plus 582 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 67 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 45 partially matching documents found.

Latest from PMHub

  • It’s all about patient outcomes… right?

    a novel biologic agent. ... Consequently, the roll-out of the novel biologic agent was conducted in a manner that was sensitive to the PCP/specialist interaction observed, ensured smooth communications and optimised patient outcomes.

  • Biotech: it's a people business

    Biologic therapies have become a central part of modern day medicine and a key part of biotech and pharma portfolios.

  • Webcast: Biosimilars: Friend or Foe to Healthcare?

    Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on

  • Infographic: RA Perceptions

    Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on

  • Biosimilars: Getting the flock to market

    originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.

More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...
fig 1
Pharma social media
Posting frequency is down as companies take a ‘less is more’ approach...
Phillip Lee
The case for a second Brexit referendum: “We need the informed consent of the people”
Dr Phillip Lee MP is fighting to keep the UK in the EMA network - and for a second referendum...